Exagen Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Exagen şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-0.3%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-0.3%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks Justified

Sep 06

Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report

Aug 07

Insufficient Growth At Exagen Inc. (NASDAQ:XGN) Hampers Share Price

Jul 13

Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?

May 21

Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge

Mar 26

Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report

Mar 22

Exagen Inc.'s (NASDAQ:XGN) Intrinsic Value Is Potentially 62% Above Its Share Price

Apr 07

Is Exagen (NASDAQ:XGN) Using Too Much Debt?

Mar 03

Exagen issues preliminary testing revenue ahead of ICT chat

Jan 11

Would Shareholders Who Purchased Exagen's (NASDAQ:XGN) Stock Year Be Happy With The Share price Today?

Jan 05

Exagen (XGN) Investor Presentation - Slideshow

Nov 20

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: XGN şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: XGN şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Exagen Piyasaya Karşı Temettü Getirisi

XGN temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (XGN)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Biotechs)	2.3%
Analist tahmini (XGN) (3 yıla kadar)	n/a

Önemli Temettü: XGN şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, XGN şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: XGN şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: XGN herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Exagen Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

Exagen Inc. Provides Earnings Guidance for the Full Year 2024

Exagen Inc. to Report Q3, 2024 Results on Nov 12, 2024

Improved Revenues Required Before Exagen Inc. (NASDAQ:XGN) Stock's 40% Jump Looks Justified

Analyst Estimates: Here's What Brokers Think Of Exagen Inc. (NASDAQ:XGN) After Its Second-Quarter Report

Exagen Inc. Revises Earnings Guidance for the Full Year 2024

Exagen Inc. Announces Chief Financial Officer Changes

Exagen Inc. Announces Chief Financial Officer Changes

Exagen Inc. to Report Q2, 2024 Results on Aug 05, 2024

Insufficient Growth At Exagen Inc. (NASDAQ:XGN) Hampers Share Price

Is Exagen (NASDAQ:XGN) Using Debt In A Risky Way?

Consensus estimates of losses per share improve by 13%

CEO, President & Director recently bought US$78k worth of stock

Exagen Inc. Updates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Exagen Inc. to Report Q1, 2024 Results on May 13, 2024

Exagen Inc., Annual General Meeting, Jun 10, 2024

Exagen Inc. Announces Changes in Board of Directors

Why Investors Shouldn't Be Surprised By Exagen Inc.'s (NASDAQ:XGN) 31% Share Price Plunge

Analysts Have Made A Financial Statement On Exagen Inc.'s (NASDAQ:XGN) Annual Report

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Exagen Inc. to Report Q4, 2023 Results on Mar 18, 2024

Exagen Inc. Reaffirms Earnings Guidance for the Full Year Ended December 31, 2023

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus estimates of losses per share improve by 11%

Exagen Inc. to Report Q3, 2023 Results on Nov 13, 2023

Price target decreased by 8.0% to US$5.75

CEO, President & Director recently sold US$59k worth of stock

New minor risk - Financial position

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Exagen Inc. to Report Q2, 2023 Results on Aug 07, 2023

Exagen Inc. Appoints Paul Kim as Class II Director

Exagen Inc.'s (NASDAQ:XGN) Business And Shares Still Trailing The Industry

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates upgraded to US$1.92 loss, revenue downgraded

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 38% to US$6.50

Exagen Inc. Announces Board Changes

Exagen Inc. Announces Executive Changes

Exagen Inc. Increases Revenue Guidance for 2022

Exagen Inc. announced delayed 10-Q filing

Exagen Inc. to Report Q3, 2022 Results on Nov 14, 2022

Exagen Inc. Appoints John Aballi as President

Exagen appoints John Aballi as CEO

Exagen Inc. Appoints Andrew L. Concoff as Chief Innovation Officer

Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients

Price target decreased to US$12.25

Consensus revenue estimates fall by 19%

Analysts Just Slashed Their Exagen Inc. (NASDAQ:XGN) EPS Numbers

Exagen Inc. Provides Revenue Guidance for the Year of 2022

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Exagen (NASDAQ:XGN) Has Debt But No Earnings; Should You Worry?

Exagen Inc. to Report Q2, 2022 Results on Aug 04, 2022

Price target decreased to US$16.40

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Exagen Inc. Revises Revenue Guidance for the Full Year of 2022

Price target decreased to US$18.00

Exagen Inc. to Report Q1, 2022 Results on May 11, 2022

Is Exagen (NASDAQ:XGN) Weighed On By Its Debt Load?

Consensus EPS estimates fall by 12%

Price target decreased to US$21.00

Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.34 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.38 loss per share (vs US$0.27 loss in 2Q 2020)

Does Exagen (NASDAQ:XGN) Have A Healthy Balance Sheet?

Exagen Inc. Announces the Publication of Their Latest Clinical Utility Study in Lupus & Science Medicine

Price target increased to US$26.75

Independent Director Jeffrey Elliott has left the company

Independent Director Jeffrey Elliott has left the company

Consensus forecasts updated

First quarter 2021 earnings released: US$0.48 loss per share (vs US$0.44 loss in 1Q 2020)

Exagen Inc. Provides Earnings Guidance for the Fiscal Year 2021

Exagen Inc.'s (NASDAQ:XGN) Intrinsic Value Is Potentially 62% Above Its Share Price

Consensus EPS estimates fall to -US$1.52